tumor mutational burden
AACR Studies Flag Molecular Differences in Colorectal Cancer Patients of African, European Ancestry
Data presented at the meeting underscored the importance of studying diverse populations in order to improve equity in precision oncology.
Merck, Moderna's Personalized Vaccine-Keytruda Combo Shines Across Biomarker Subgroups at AACR
Adding Moderna's vaccine to Merck's checkpoint inhibitor in the adjuvant treatment setting benefited melanoma patients, even across biomarker groups like TMB and PD-L1.
Epic Sciences Raises $24M, Expands Commercial Infrastructure for Breast Cancer Liquid Biopsy Test
The firm is growing its sales, product marketing, and customer service teams for its multiomic metastatic breast cancer liquid biopsy test, DefineMBC.
Merck Nabs Full FDA Approval for Keytruda in MSI-High, dMMR Solid Tumors
The conversion from accelerated to full approval marks the first time the FDA has granted full approval to an immunotherapy in a tumor-agnostic indication.
The company has derived and validated a mutational and gene expression score that predicts immunotherapy benefit across tumor types.